Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri.
Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri; Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Florence, Italy.
J Pain. 2019 Aug;20(8):956-964. doi: 10.1016/j.jpain.2019.02.007. Epub 2019 Feb 23.
Sphingosine-1-phosphate (S1P) receptor 1 subtype (S1PR1) activation by its ligand S1P in the dorsal horn of the spinal cord causes mechanohypersensitivity. The cellular and molecular pathways remain poorly understood. We report that the activation of S1PR1 with an intrathecal injection of the highly selective S1PR1 agonist SEW2871 led to the development of mechanoallodynia by activating the nod-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome (increased expression of NLRP3, cleaved caspase 1 and mature IL-1β) in the dorsal horn of the spinal cord. The functional S1PR1 antagonist FTY720 blocked NLRP3 activation and IL-1β production. Moreover, inhibiting IL-10 signaling with an intrathecal injection of an anti-IL-10 antibody attenuated the beneficial effects exerted by FTY720. This finding suggests that disrupting S1PR1 signaling engages beneficial IL-10-dependent pathways. Notably, we found that mice with astrocyte-specific deletions of S1pr1 did not develop mechanoallodynia after intrathecal injection of SEW2871 and exhibited decreased levels of cleaved caspase 1, identifying astrocytes as a key cellular locus for S1PR1 activity. Our findings provide novel mechanistic insights on how S1PR1 activation in the spinal cord contributes to the development of nociception while identifying the cellular substrate for these activities. PERSPECTIVE: This study is the first to link the activation of NLRP3 and IL-1β signaling in the spinal cord and S1PR1 signaling in astrocytes to the development of S1PR1-evoked mechanoallodynia. These findings provide critical basic science insights to support the development of therapies targeted toward S1PR1.
鞘氨醇-1-磷酸(S1P)受体 1 亚型(S1PR1)在脊髓背角被其配体 S1P 激活后会导致机械性痛觉过敏。但细胞和分子途径仍知之甚少。我们报告称,鞘氨醇-1-磷酸受体 1 激动剂 SEW2871 鞘内注射激活 S1PR1,可通过激活脊髓背角的 NOD 样受体家族,富含吡啶结构域的 3(NLRP3)炎性小体(NLRP3、切割的半胱天冬酶 1 和成熟的 IL-1β表达增加)导致机械性痛觉过敏。功能性 S1PR1 拮抗剂 FTY720 阻断 NLRP3 激活和 IL-1β 产生。此外,鞘内注射抗 IL-10 抗体抑制 IL-10 信号转导,可减弱 FTY720 的有益作用。这一发现表明,破坏 S1PR1 信号会引发有益的依赖于 IL-10 的途径。值得注意的是,我们发现鞘氨醇-1-磷酸受体 1 在星形胶质细胞中的特异性缺失小鼠在鞘内注射 SEW2871 后不会发展为机械性痛觉过敏,并且切割的半胱天冬酶 1 水平降低,这表明星形胶质细胞是 S1PR1 活性的关键细胞定位。我们的研究结果提供了新的机制见解,说明了脊髓中 S1PR1 的激活如何导致痛觉过敏的发展,同时确定了这些活性的细胞基础。观点:本研究首次将脊髓中 NLRP3 和 IL-1β 信号的激活以及星形胶质细胞中的 S1PR1 信号与 S1PR1 诱发的机械性痛觉过敏的发展联系起来。这些发现为靶向 S1PR1 的治疗方法的开发提供了重要的基础科学见解。